Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy

被引：2

作者：

D'Addona, Matteo ^{[1
]}

Pezzullo, Luca ^{[1
]}

Giudice, Valentina ^{[1
,2
]}

Serio, Bianca ^{[1
]}

Baldi, Carlo ^{[3
]}

Zeppa, Pio ^{[2
,3
]}

Selleri, Carmine ^{[1
,2
]}

机构：

[1] Univ Hosp San Giovanni Dio & Ruggi dAragona, Hematol & Transplant Ctr, Salerno, Italy

[2] Univ Salerno, Dept Med Surg & Dent, Baronissi, Italy

[3] Univ Hosp San Giovanni Dio & Ruggi dAragona, Anat Pathol, Salerno, Italy

来源：

CLINICAL CASE REPORTS | 2022年 / 10卷 / 06期

关键词：

BCR-ABL; inhibitor; chronic myeloid leukemia; Kaposi's sarcoma; INTERFERON-ALPHA;

D O I：

10.1002/ccr3.5919

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Kaposi's sarcoma is associated with immunosuppression and human herpesvirus 8 infection, while rarely described in myeloid malignancies. Here, we illustrate a rare case of chronic myeloid leukemia treated with imatinib, a tyrosine kinase inhibitor, who developed a human herpesvirus 8-related Kaposi's sarcoma.

引用

页数：4

共 50 条

[41] Translocation t(7;12) in a patient with chronic myeloid leukemia receiving Imatinib Mesylate therapy
Bennour, A.
Sennana, H.
Achour, B.
Ben Youssef, Y.
Zaier, M.
Khelif, A.
Saad, A.
CHROMOSOME RESEARCH, 2009, 17 : 119 - 120
[42] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
Kiguchi, Toru
Tauchi, Tetsuzo
Ito, Yoshikazu
Miyazawa, Keisuke
Kimura, Yukihiko
Ohyashiki, Kazuma
LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
[43] Comparative study of safety and efficacy of imatinib mesylate therapy in pediatric and adult chronic myeloid leukemia
Raizada, N.
Sagar, T.
Ramanan, S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[44] Imatinib mesylate in chronic myeloid leukemia of childhood: From care to cure?
Warrier, Arun
Santa, Ayyagari
Sagar, T. G.
PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 577 - 577
[45] Imatinib mesylate can induce molecular remissions in chronic myeloid leukemia
Lawler, M
Gately, K
Ryan, J
Carroll, P
Howard, J
Stallings, R
Conneally, E
McCann, S
BONE MARROW TRANSPLANTATION, 2003, 31 : S160 - S160
[46] Drug Efflux Transporters and Imatinib Mesylate Insensitivity in Chronic Myeloid Leukemia
Aquino Moreira-Nunes, Caroline Fatima
Simoes Beltrao, Ana Cristina
Valente Martins Frances, Larissa Tatiana
Mattos Amaral Sousa, Rodrigo Guarischi
Silva, Israel Tojal
Silva, Artur Luiz
Silva-, Wilson Araujo, Jr.
Rodrigues Lemos, Jose Alexandre
BLOOD, 2012, 120 (21)
[47] IMATINIB MESYLATE INDUCED HEPATOTOXICITY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
Milosevic, V.
Bogdanovic, A.
Djordjevic, V.
Fekete, M. Dencic
Mihaljevic, B.
Gotic, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 545 - 546
[48] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Arora, B
Kumar, L
Sharma, A
Wadhwa, J
Kochupillai, V
ANNALS OF ONCOLOGY, 2004, 15 (02) : 358 - 359
[49] Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate
Lakshmaiah, K. C.
Bhise, Rohan
Purohit, Samit
Abraham, Linu J.
Lokanatha, D.
Suresh, T. M.
Appaji, L.
Arunakumari, B. S.
Govindbabu, K.
LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2430 - 2433
[50] The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia
Eskazan, Ahmet Emre
Elverdi, Tugrul
Yalniz, Fevzi Firat
Salihoglu, Ayse
Ar, Muhlis Cem
Aydin, Seniz Ongoren
Baslar, Zafer
Aydin, Yildiz
Tuzuner, Nukhet
Ozbek, Ugur
Soysal, Teoman
LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2935 - 2937

← 1 2 3 4 5 →